Harry J. Iland

Missenden Road
Camperdown, NSW 2050, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

APOLLO: Optimizing the Treatment of High-Risk Acute Promyelocytic Leukemia With All-Trans Retinoic Acid and Arsenic Trioxide While Minimizing the Role of Chemotherapy.

APOLLO: Optimizing the Treatment of High-Risk Acute Promyelocytic Leukemia With All-Trans Retinoic Acid and Arsenic Trioxide While Minimizing the Role of Chemotherapy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 18, 2025

Measurable residual disease intervention in AML: a new therapeutic horizon.

Measurable residual disease intervention in AML: a new therapeutic horizon.

Journal: Blood

Published: July 24, 2025

Advancing diagnostic targeted RNA sequencing for haematological malignancies within an Australian sample exchange program.

Advancing diagnostic targeted RNA sequencing for haematological malignancies within an Australian sample exchange program.

Journal: Pathology

Published: March 23, 2025

Patients with high-risk acute promyelocytic leukemia need maintenance therapy for 1 year - the CONS.

Patients with high-risk acute promyelocytic leukemia need maintenance therapy for 1 year - the CONS.

Journal: Haematologica

Published: March 17, 2025

In APL, 2 targets are better than 1!

In APL, 2 targets are better than 1!

Journal: Blood

Published: January 09, 2025

ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL.

ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL.

Journal: Blood advances

Published: November 18, 2024

FLT3-TKD Measurable Residual Disease Detection Using Droplet Digital PCR and Clinical Applications in Acute Myeloid Leukemia.

FLT3-TKD Measurable Residual Disease Detection Using Droplet Digital PCR and Clinical Applications in Acute Myeloid Leukemia.

Journal: International journal of molecular sciences

Published: March 28, 2024

Arsenic-induced neurotoxicity in patients with acute promyelocytic leukaemia.

Arsenic-induced neurotoxicity in patients with acute promyelocytic leukaemia.

Journal: British journal of haematology

Published: November 15, 2023

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.

Journal: Blood

Published: March 28, 2023

Applying molecular measurable residual disease testing in acute myeloid leukaemia.

Applying molecular measurable residual disease testing in acute myeloid leukaemia.

Journal: Pathology

Published: September 29, 2022

Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation.

Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation.

Journal: Blood advances

Published: July 18, 2022

Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia.

Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia.

Journal: Blood advances

Published: November 23, 2021

Showing 1-12 of 37

Last Updated: 09/26/2026